Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 11:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 613 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: iron Clear all

Conditions: Iron Deficiency Anemia
Interventions: Ferumoxytol, Saline, Ferrous sulfate tablets, Vitamin C; Drug
Lead sponsor: Auerbach Hematology Oncology Associates P C; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Anemia
Interventions: Not listed
Lead sponsor: Cornell University; Other
Eligibility: 19 Years to 45 Years · Female only
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2023
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Iron Deficiency, Iron Deficiency Anemia
Interventions: Iron-containing food product; Other
Lead sponsor: United States Army Research Institute of Environmental Medicine; Federal
Eligibility: 18 Years to 42 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Iron Absorption
Interventions: Exercise test; Other
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 45 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Iron Deficiency, Fibromyalgia
Interventions: Injectafer, Placebo; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Franklin, Tennessee

Conditions: Vasoconstriction, Vasodilation
Interventions: Handgrip Exercise Training, Acetylcholine, Adenosine Triphosphate, Atropine, Phenylephrine, Sodium Nitroprusside; Other · Drug
Lead sponsor: Colorado State University; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Diabetes Mellitus, Type 1
Interventions: Anti-CD3 mAb, Diabetes Standard of Care Treatment, Iron supplementation; Biological · Other · Dietary Supplement
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 8 Years to 30 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 7
States / cities: San Francisco, California • Denver, Colorado • New Haven, Connecticut + 3 more

Conditions: Anemia, Surgery
Interventions: Monoferric; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Heart Failure
Interventions: Sodium nitroprusside, Dobutamine, Furosemide; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Iron Deficiency
Interventions: Not listed
Lead sponsor: Cornell University; Other
Eligibility: 15 Years to 35 Years · Female only
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Rochester, New York

Conditions: Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis
Interventions: AP301, AP301 Low Dose; Drug
Lead sponsor: Alebund Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 18
States / cities: Granada Hills, California • San Dimas, California • Lone Tree, Colorado + 14 more

Conditions: Anemia, Iron-Deficiency, Kidney Failure, Chronic
Interventions: Sodium Ferric Gluconate complex in sucrose, Ferrous sulfate tablets; Drug
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 23
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 20 more

Conditions: Iron Deficiency Anemia (IDA)
Interventions: Not listed
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Norristown, Pennsylvania

Conditions: Anemia, Iron Deficiency, Iron Overload
Interventions: Not listed
Lead sponsor: Cornell University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 515 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 2
States / cities: Ithaca, New York • Rochester, New York

Conditions: Mucormycosis
Interventions: deferasirox, Placebo, Liposomal amphotericin B; Drug
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 2 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 7
States / cities: Duarte, California • San Francisco, California • Miami, Florida + 4 more

Conditions: Diagnostic Errors
Interventions: Quality Improvement Collaborative; Behavioral
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 26 Years and older
Enrollment: 13,853 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Elk Grove Village, Illinois

Conditions: Beta-thalassemia, Iron Overload
Interventions: Deferasirox; Drug
Lead sponsor: Novartis; Industry
Eligibility: 10 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: Los Angeles, California • Oakland, California • Chicago, Illinois

Conditions: Anemia, Sickle Cell
Interventions: ICL670, deferoxamine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 34
States / cities: Mobile, Alabama • Loma Linda, California • Los Angeles, California + 25 more

Conditions: Iron, Diabetes, Nonalcoholic Fatty Liver
Interventions: Blood Donation, Sham Blood Donation; Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 40 Years to 75 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Winston-Salem, North Carolina

Conditions: Iron-deficiency
Interventions: Synbiotic Supplement, Placebo; Dietary Supplement
Lead sponsor: Marywood University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Scranton, Pennsylvania

Conditions: Anemia, Iron Deficiency, Heavy Menstrual Bleeding
Interventions: Ferumoxytol, Ferrous Sulfate; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Renal Insufficiency, Chronic, Anemia, Iron Deficiency, Anemia of Chronic Kidney Disease
Interventions: Model predictive control, Model Predictive Control of Iron Dosing; Device
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Iron Deficiency Anemia, Pregnancy
Interventions: Ferric derisomaltose, Ferrous sulfate; Drug
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Birmingham, Alabama • Miami, Florida • Ann Arbor, Michigan + 4 more

Conditions: Anemia, Iron Deficiency Anemia
Interventions: Treatment with oral sucrosomial iron, Treatment with intravenous iron; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Rochester, New York

Search by objective public record fields.

Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient

Determinants of Neonatal Anemia in Women Carrying Multiples

An Iron-containing Food Product for the Prevention of Diminished Iron Status in Soldiers

The Effects of Acute Erythropoietin on Hepcidin and Dietary Iron Absorption Following Military-relevant Exercise in Energy Deficit: Pilot Study

Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia

Role of Acetylcholine in Blood Flow Regulation in Healthy Adults: Effects of Age and Exercise Training

Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes

Preoperative Monoferric for Abdominal Surgery

Intravenous Vasodilator vs. Inotropic Therapy in Patients With Heart Failure

Absorption of Heme and Non-Heme Iron in Pregnant and Non-pregnant Women and Mechanisms of Fetal Iron Transfer

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic Agents

Observational Study on the Use of IV (Intravenous) Iron Therapy Among Subjects With Iron Deficiency Anemia

Ethnic Differences in Iron Absorption (FeGenes)

The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study

Reducing Diagnostic Errors in Primary Care Pediatrics (Project RedDE)

Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment

Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions

Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease

How Does a Synbiotic Supplement Affect Iron Status During Iron Repletion in Iron Depleted Female Athletes?

IV Iron vs Oral Iron for Treatment of Anemia in Women With Abnormal Uterine Bleeding

Iron Dosing Pilot Study Using Model Predictive Control

Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy

Sucrosomial Vs Intravenous Iron for Preoperative Anemia